Toxicity of Pioglitazone on Mitochondria Isolated from Brain and Heart: An Analysis for Probable Drug-Induced Neurotoxicity and Cardiotoxicity

Abstract

Pioglitazone (PG) is one of the thiazolidinedione (TZDs) drugs used in diabetic patients. TZDs are known as peroxisome proliferator-activated receptor gamma (PPARγ) agonists. Mitochondria are considered as one of the targets of these drugs. The mechanisms of the effect of PG on mitochondria are not well understood. In this study, we investigated the effect of PG on mitochondria isolated from brain and heart. Mitochondrial parameters such as succinate dehydrogenase (SDH) activity, reactive oxygen species (ROS) generation, collapse in mitochondrial membrane potential (MMP), mitochondrial swelling and cytochrome c release were evaluated. The results showed that PG at concentrations of 12.5, 25 and 50 µg/ml increased the generation of ROS, the collapse of MMP, mitochondrial swelling and the release of cytochrome c in mitochondria isolated from both brain and heart tissues. The underlying mechanisms of PG induced neuro-toxicity and cardio-toxicity may be associated with changes in mitochondrial function, ROS generation (oxidative stress), and changes in the mitochondrial membrane.

Key words

pharmacology - toxicology - apoptosis

• References

• 1 Divakaruni AS, Wiley SE, Rogers GW. et al. Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier. Proc Natl Acad Sci USA 2013; 110: 5422-5427
• 2 Hu D, Wu CQ, Li ZJ. et al. Characterizing the mechanism of thiazolidinedione-induced hepatotoxicity: An in vitro model in mitochondria. Toxicol Appl Pharmacol 2015; 284: 134-141
• 3 Perez-Ortiz JM, Tranque P, Vaquero CF. et al. Glitazones differentially regulate primary astrocyte and glioma cell survival. Involvement of reactive oxygen species and peroxisome proliferator-activated receptor-gamma. J Biol Chem 2004; 279: 8976-8985
• 4 Sanz MN, Sanchez-Martin C, Detaille D. et al. Acute mitochondrial actions of glitazones on the liver: A crucial parameter for their antidiabetic properties. Cell Physiol Biochem 2011; 28: 899-910
• 5 He H, Tao H, Xiong H. et al. Rosiglitazone causes cardiotoxicity via peroxisome proliferator-activated receptor gamma-independent mitochondrial oxidative stress in mouse hearts. Toxicol Sci 2014; 138: 468-481
• 6 Skov V, Glintborg D, Knudsen S. et al. Pioglitazone enhances mitochondrial biogenesis and ribosomal protein biosynthesis in skeletal muscle in polycystic ovary syndrome. PLoS One 2008; 3: e2466
• 7 Giles TD, Miller AB, Elkayam U. et al. Pioglitazone and heart failure: Results from a controlled study in patients with type 2 diabetes mellitus and systolic dysfunction. Journal of Cardiac Failure 2008; 14: 445-452
• 8 Liao H-W, Saver JL, Wu Y-L. et al. Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis. BMJ Open 2017; 7: e013927
• 9 Nesto RW, Bell D, Bonow RO. et al. Thiazolidinedione use, fluid retention, and congestive heart failure: A consensus statement from the American Heart Association and American Diabetes Association. Circulation 2003; 108: 2941-2948
• 10 Beheshti F, Hosseini M, Hashemzehi M. et al. The effects of PPAR-gamma agonist pioglitazone on hippocampal cytokines, brain-derived neurotrophic factor, memory impairment, and oxidative stress status in lipopolysaccharide-treated rats. Iran J Basic Med Sci 2019; 22: 940-948
• 11 McGuire JL, Correll EA, Lowery AC. et al. Pioglitazone improves working memory performance when administered in chronic TBI. Neurobiol Dis 2019; 132: 104611
• 12 Quan Q, Qian Y, Li X. et al. Pioglitazone Reduces beta Amyloid Levels via Inhibition of PPARgamma Phosphorylation in a Neuronal Model of Alzheimer’s Disease. Front Aging Neurosci 2019; 11: 178
• 13 Pourahmad J, Hosseini MJ. Application of isolated mitochondria in toxicological and clinical studies. Iran J Pharm Res 2012; 11: 703-704
• 14 Bova MP, Tam D, McMahon G. et al. Troglitazone induces a rapid drop of mitochondrial membrane potential in liver HepG2 cells. Toxicol Lett 2005; 155: 41-50
• 15 Castro JP, Wardelmann K, Grune T. et al. Mitochondrial Chaperones in the Brain: Safeguarding Brain Health and Metabolism?. Front Endocrinol (Lausanne) 2018; 9: 196
• 16 Zhao Q, Sun Q, Zhou L. et al. Complex Regulation of Mitochondrial Function During Cardiac Development. J Am Heart Assoc 2019; 8: e012731
• 17 Dello Russo C, Gavrilyuk V, Weinberg G. et al. Peroxisome proliferator-activated receptor gamma thiazolidinedione agonists increase glucose metabolism in astrocytes. J Biol Chem 2003; 278: 5828-5836
• 18 Sun L, Yuan Q, Xu T. et al. Pioglitazone improves mitochondrial function in the remnant kidney and protects against renal fibrosis in 5/6 nephrectomized rats. Front Pharmacol 2017; 8: 545
• 19 Masubuchi Y, Kano S, Horie T. Mitochondrial permeability transition as a potential determinant of hepatotoxicity of antidiabetic thiazolidinediones. Toxicology 2006; 222: 233-239
• 20 Quintanilla RA, Jin YN, Fuenzalida K. et al. Rosiglitazone treatment prevents mitochondrial dysfunction in mutant huntingtin-expressing cells: Possible role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in the pathogenesis of Huntington disease. J Biol Chem 2008; 283: 25628-25637
• 21 Rachek LI, Yuzefovych LV, Ledoux SP. et al. Troglitazone, but not rosiglitazone, damages mitochondrial DNA and induces mitochondrial dysfunction and cell death in human hepatocytes. Toxicol Appl Pharmacol 2009; 240: 348-354
• 22 Rezaiean Mehrabadi A, Jamshidzadeh A, Rashedinia M. et al. Study of the effects of ATP suppliers and thiol reductants on toxicity of pioglitazone in isolated rat liver mitochondria. Iran J Pharm Res 2015; 14: 825-832
• 23 Shannon CE, Daniele G, Galindo C. et al. Pioglitazone inhibits mitochondrial pyruvate metabolism and glucose production in hepatocytes. Febs J 2017; 284: 451-465
• 24 Munro D, Treberg JR. A radical shift in perspective: Mitochondria as regulators of reactive oxygen species. J Exp Biol 2017; 220 1170-1180
• 25 Murphy MP. How mitochondria produce reactive oxygen species. Biochem J 2009; 417: 1-13
• 26 Rigoulet M, Yoboue ED, Devin A. Mitochondrial ROS generation and its regulation: Mechanisms involved in H(2)O(2) signaling. Antioxid Redox Signal 2011; 14: 459-468
• 27 Zhao RZ, Jiang S, Zhang L. et al. Mitochondrial electron transport chain, ROS generation and uncoupling (Review). Int J Mol Med 2019; 44: 3-15
• 28 Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry 1976; 72: 248-254
• 29 Zhao Y, Ye L, Liu H. et al. Vanadium compounds induced mitochondria permeability transition pore (PTP) opening related to oxidative stress. J Inorg Biochem 2010; 104: 371-378
• 30 Salimi A, Eybagi S, Seydi E. et al. Toxicity of macrolide antibiotics on isolated heart mitochondria: A justification for their cardiotoxic adverse effect. Xenobiotica 2016; 46: 82-93
• 31 Baracca A, Sgarbi G, Solaini G. et al. Rhodamine 123 as a probe of mitochondrial membrane potential: Evaluation of proton flux through F(0) during ATP synthesis. Biochim Biophys Acta 2003; 1606: 137-146
• 32 Hsiao PJ, Chiou HC, Jiang HJ. et al. Pioglitazone enhances cytosolic lipolysis, beta-oxidation and autophagy to ameliorate hepatic steatosis. Sci Rep 2017; 7: 9030
• 33 Picard M, McEwen BS. Mitochondria impact brain function and cognition. Proc Natl Acad Sci USA 2014; 111: 7-8
• 34 Rango M, Bresolin N. Brain Mitochondria, Aging, and Parkinson’s Disease. Genes (Basel) 2018; 9: 5
• 35 Griffiths EJ. Mitochondria and heart disease. Adv Exp Med Biol 2012; 942: 249-267
• 36 Siasos G, Tsigkou V, Kosmopoulos M. et al. Mitochondria and cardiovascular diseases-from pathophysiology to treatment. Ann Transl Med 2018; 6: 256
• 37 Dan Dunn J, Alvarez LA, Zhang X. et al. Reactive oxygen species and mitochondria: A nexus of cellular homeostasis. Redox Biol 2015; 6: 472-485
• 38 Sena LA, Chandel NS. Physiological roles of mitochondrial reactive oxygen species. Mol Cell 2012; 48: 158-167
• 39 Zorov DB, Juhaszova M, Sollott SJ. Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. Physiol Rev 2014; 94: 909-950
• 40 Nissanka N, Moraes CT. Mitochondrial DNA damage and reactive oxygen species in neurodegenerative disease. FEBS Lett 2018; 592: 728-742
• 41 Seydi E, Rasekh HR, Salimi A. et al. Selective toxicity of apigenin on cancerous hepatocytes by directly targeting their mitochondria. Anticancer Agents Med Chem 2016; 16: 1576-1586
• 42 Stefanatos R, Sanz A. The role of mitochondrial ROS in the aging brain. FEBS Lett 2018; 592: 743-758
• 43 Gottlieb E, Armour SM, Harris MH. et al. Mitochondrial membrane potential regulates matrix configuration and cytochrome c release during apoptosis. Cell Death Differ 2003; 10: 709-717